Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity

Current Rheumatology Reports

Volumn 10, Issue 3, 2008, Pages 195-204

  Todd, Derrick J ^b   Kay, Jonathan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; SODIUM THIOSULFATE; THALIDOMIDE; CONTRAST MEDIUM;

ARTHRALGIA; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; GADOLINIUM ASSOCIATED SYSTEMIC FIBROSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; LIPODERMATOSCLEROSIS; MYALGIA; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PORPHYRIA CUTANEA TARDA; PRURITUS; REVIEW; SCLERODERMA; SCLEROMYXEDEMA; SEIZURE; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN DEFECT; SKIN FIBROSIS; SKIN TIGHTNESS; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FIBROSIS; KIDNEY; PATHOLOGY; SKIN; SKIN DISEASE;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; SKIN; SKIN DISEASES;

EID: 51449109627     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0033-6     Document Type: Review

References (90)

1. Cowper SE, Robin HS, Steinberg SM, et al.: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356:1000-1001.
2. Cowper SE, Su LD, Bhawan J, et al.: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23:383-393.
3. Ting WW, Stone MS, Madison KC, Kurtz K: Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003, 139:903-906.
4. Thomsen HS: Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 2006, 16:2619-2621.
5. Cowper SE, Bucala R, Leboit PE: Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis - setting the record straight. Semin Arthritis Rheum 2006, 35:208-210.
6. Grobner T: Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006, 21:1104-1108.
7. Marckmann P, Skov L, Rossen K, et al.: Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006, 17:2359-2362.
8. Kay J: Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med 2008, 75:112, 114, 117.
9. Auron A, Shao L, Warady BA: Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 2006, 21:1307-1311.
10. Swartz RD, Crofford LJ, Phan SH, et al.: Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003, 114:563-572.
11. Kalb RE, Helm TN, Sperry H, et al.: Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008, 158:607-610.
12. Mendoza FA, Artlett CM, Sandorfi N, et al.: Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006, 35:238-249.
13. Broome DR, Girguis MS, Baron PW, et al.: Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned. Am J Roentgenol 2007, 188:586-592.
14. Todd DJ, Kagan A, Chibnik LB, Kay J: Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007, 56:3433-3441.
15. Rydahl C, Thomsen HS, Marckmann P: High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008, 43:141-144.
16. Centers for Disease Control and Prevention (CDC): Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007, 56:137-141.
17. Baron PW, Cantos K, Hillebrand DJ, et al.: Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003, 25:204-209.
18. Maloo M, Abt P, Kashyap R, et al.: Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006, 6:2212-2217.
19. Swaminathan S, Ahmed I, McCarthy JT, et al.: Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006, 145:234-235.
20. Marckmann P, Skov L, Rossen K, et al.: Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007, 22:3174-3178.
21. Dharnidharka VR, Wesson SK, Fennell RS: Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2007, 22:1395.
22. Fazeli A, Lio PA, Liu V: Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 2004, 140:1401.
23. Swaminathan S, Horn TD, Pellowski D, et al.: Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007, 357:720-722.
24. Moschella SL, Kay J, Mackool BT, Liu V: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004, 351:2219-2227.
25. Kay J, Kagan A, Chibnik LB, et al.: Nephrogenic fibrosing dermopathy develops following gadopentetate dimeglumine exposure [abstract]. Arthritis Rheum 2007, 56(Suppl): S546-S547.
26. Streams BN, Liu V, Liegeois N, Moschella SM: Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 2003, 48:42-47.
27. Daram SR, Cortese CM, Bastani B: Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005, 46:754-759.
28. Jimenez SA, Artlett CM, Sandorfi N, et al.: Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004, 50:2660-2666.
29. Gibson SE, Farver CF, Prayson RA: Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006, 130:209-212.
30. Kucher C, Steere J, Elenitsas R, et al.: Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006, 54(2 Suppl):S31-34.
31. Saenz A, Mandal R, Kradin R, Hedley-Whyte ET: Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006, 449:389-391.
32. Kay J, Bazari H, Avery LL, Koreishi AF: Case records of the Massachusetts General Hospital. Case 6-2008. A 46-yearold woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008, 358:827-838.
33. Edsall LC, English 3rd JC, Patterson JW: Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004, 31:247-253.
34. Bucala R: Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 2008, 5:36-39.
35. Centers for Disease Control and Prevention (CDC): Eosinophilia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minnesota, Oregon, and New York, 1989. MMWR Morb Mortal Wkly Rep 1989, 38:785-788.
36. Martinez-Tello FJ, Navas-Palacios JJ, Ricoy JR, et al.: Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain. Virchows Archiv 1982, 397:261-285.
37. Evenepoel P, Zeegers M, Segaert S, et al.: Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004, 19:469-473.
38. Kucher C, Xiaowei X, Pasha T, Elenitsas R: Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 2005, 32:484-490.
39. Dixon AJ, Dixon MP, Askew DA, Wilkinson D: Prospective study of wound infections in dermatologic surgery in the absence of prophylactic antibiotics. Dermatol Surg 2006, 32:819-826; discussion 826-817.
40. Bloom H, Heeke B, Leon A, et al.: Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol 2006, 29:142-145.
41. Bogoch ER, Gross DK: Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005, 32:642-648.
42. Ahmed I, Goldstein B: Diabetes mellitus. Clin Dermatol 2006, 24:237-246.
43. Alguire PC, Mathes BM: Skin biopsy techniques for the internist. J Gen Intern Med 1998, 13:46-54.
44. Collidge TA, Thomson PC, Mark PB, et al.: Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007, 245:168-175.
45. Othersen JB, Maize JC Jr, Woolson RF, Budisavljevic MN: Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007, 22:3179-3185.
46. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Acad Nephrol 2007, 1:264-267.
47. Behra-Miellet J, Gressier B, Brunet C, et al.: Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Method Find Exp Clin Pharmacol 1996, 18:437-442.
48. Husztik E, Lazar G, Parducz A: Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol 1980, 61:624-630.
49. Itoh N, Kawakita M: Characterization of Gd3+ and Tb3+ binding sites on Ca2+,Mg2+-adenosine triphosphatase of sarcoplasmic reticulum. J Biochem 1984, 95:661-669.
50. Spencer AJ, Wilson SA, Batchelor J, et al.: Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997, 25:245-255.
51. Biagi BA, Enyeart JJ: Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. Am J Physiol 1990, 259:C515-520.
52. Lansman JB: Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit. J Gen Physiol 1990, 95:679-696.
53. Boyd AS, Zic JA, Abraham JL: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007, 56:27-30.
54. Vorobiov M, Basok A, Tovbin D, et al.: Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003, 18:884-887.
55. Idee JM, Port M, Raynal I, et al.: Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006, 20:563-576.
56. Mann JS: Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 1993, 17(Suppl 1):S19-23.
57. VanWagoner M, O'Toole M, Worah D, et al.: A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1991, 26:980-986.
58. Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998, 5:491-502.
59. Johnson DB, Lerner CA, Prince MR, et al.: Gadolinium-enhanced magnetic resonance angiography of renal transplants. Magn Reson Imaging 1997, 15:13-20.
60. Arsenault TM, King BF, Marsh JW Jr, et al.: Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996, 71:1150-1154.
61. Sam AD, Morasch MD, Collins J, et al.: Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003, 38:313-318.
62. US Food and Drug Administration: Public Health Advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at www.fda.gov/cder/drug/advisory/gadolinium_agents.htm. Accessed March 14, 2008.
63. Abraham JL, Thakral C, Skov L, et al.: Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008, 158:273-280.
64. Grobner T: Author reply. Nephrol Dial Transplant 2006, 21:3604-3605.
65. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE: Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007, 242:647-649.
66. Sadowski EA, Bennett LK, Chan MR, et al.: Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243:148-157.
67. High WA, Ayers RA, Chandler J, et al.: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007, 56:21-26.
68. High WA, Ayers RA, Cowper SE: Gadolinium is quantifi able within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007, 56:710-712.
69. White GW, Gibby WA, Tweedle MF: Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006, 41:272-278.
70. Saussereau E, Lacroix C, Cattaneo A, et al.: Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 2008, 176:54-57.
71. Wahba IM, Simpson EL, White K: Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007, 7:2425-2432.
72. Thakral C, Alhariri J, Abraham JL: Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007, 2:199-205.
73. Harpur ES, Worah D, Hals PA, et al.: Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993, 28(Suppl 1):S28-43.
74. Levine JM, Taylor RA, Elman LB, et al.: Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004, 30:569-577.
75. Pieringer H, Schmekal B, Janko O, Biesenbach G: Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007, 22:3094.
76. Chung HJ, Chung KY: Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 2004, 150:596-597.
77. Hubbard V, Davenport A, Jarmulowicz M, Rustin M: Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 2003, 148:563-568.
78. Gilliet M, Cozzio A, Burg G, Nestle FO: Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005, 152:531-536.
79. Richmond H, Zwerner J, Kim Y, Fiorentino D: Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007, 143:1025-1030.
80. Yerram P, Saab G, Karuparthi PR, et al.: Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Acad Nephrol 2007, 1:258-263.
81. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
82. Daniels CE, Wilkes MC, Edens M, et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
83. Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Faseb J 2005, 19:1-11.
84. Distler JH, Jungel A, Huber LC, et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322.
85. Kay J, High WA: Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008 (in press).
86. Duff G: Gadolinium-containing MRI contrast agents and nephrogenic systemic fibrosis (NSF). Available at http://www.ismrm.org/special/ EMEA1.pdf. Accessed March 14, 2008.
87. US Food and Drug Administration: Information for Health Care Professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/ gcca_200705HCP.pdf. Accessed March 14, 2008.
88. Bayer HealthCare Pharmaceuticals: Magnevist safety information: Nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/ NFD). Available at http://www.berleximaging.com/html/magnevist/ nsf_nfd.html. Accessed March 14, 2008.
89. Flaten H: Omniscan. Available at http://www.omniscan-news.com/ letter.shtml. Accessed March 14, 2008.
90. Lauenstein TC, Salman K, Morreira R, et al.: Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007, 26:1198-1203.